You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

14 Items
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Cancer Type: Breast     
Intent: Adjuvant, Neoadjuvant, Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
Updated
Dec 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade     
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab - HIV-Related, Aggressive Histology, B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (SC) - HIV-Related - Aggressive Histology - B-cell Lymphoma
Jun 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Ipilimumab - Previously Untreated Advanced Unresectable Melanoma
New Drug Funding Program
    Ipilimumab - Previously Treated Advanced Unresectable Melanoma
Updated
Nov 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab - As Part of the MATRix Regimen in Newly Diagnosed, Previously Untreated PCNSL
May 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Apr 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab – Metastatic Renal Cell Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab – Metastatic Renal Cell Carcinoma
May 2019
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Aug 2019
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Funding:
New Drug Funding Program
    Topotecan - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Topotecan - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Aug 2017
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Funding:
New Drug Funding Program
    Topotecan - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Aug 2017